extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
5d95f7ea1d
commit
6f36fd5dbd
4 changed files with 35 additions and 1 deletions
|
|
@ -49,6 +49,12 @@ The 92% figure applies to 'deploying, implementing, or piloting' ambient AI as o
|
|||
|
||||
WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural facilities in March 2026, one month after Epic AI Charting launch. This rural expansion suggests ambient AI has passed from pilot phase to broad deployment phase, as enterprise technology typically enters academic medical centers first, then regional health systems, then rural/critical access hospitals last. The fact that a state academic health system serving one of the most rural and medically underserved states chose to expand Abridge post-Epic launch provides implicit market validation of Abridge's competitive position.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
|
||||
|
||||
OpenEvidence demonstrates that clinical reasoning support (not just documentation) can achieve comparable adoption velocity—40%+ of US physicians daily within two years—but with persistent trust barriers: 44% concerned about accuracy/misinformation and 19% concerned about lack of physician oversight, even among heavy users. This suggests clinical reasoning AI faces adoption friction that documentation AI does not.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -17,6 +17,12 @@ What makes this significant is the adoption speed. Reaching 40% of US physicians
|
|||
|
||||
The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
|
||||
|
||||
OpenEvidence reached 20M clinical consultations/month by January 2026 (2,000%+ YoY growth from 8.5M/month in 2025), achieved 1M consultations in a single day on March 10, 2026, and is now valued at $12B (up from $3.5B, tripling in months). Used across 10,000+ hospitals nationwide. First AI to score 100% on all parts of USMLE.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -17,6 +17,12 @@ A deeper finding from a Stanford/Harvard study challenges even the "similar accu
|
|||
|
||||
The implication for AI deployment strategy: the highest-value clinical AI applications are not diagnostic augmentation but workflow automation (ambient documentation, administrative burden reduction) and safety netting (AI triage catching missed findings). The centaur model may still apply to medicine, but the interaction design must prevent physicians from overriding AI on tasks where AI demonstrably outperforms -- a politically and ethically charged constraint.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
|
||||
|
||||
OpenEvidence's 100% USMLE score and scale to 20M monthly consultations with 40%+ of US physicians creates the first real-world test case at population scale. However, no peer-reviewed outcomes data exists showing whether OpenEvidence-assisted consultations produce better patient outcomes despite the benchmark achievement and massive adoption.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -7,9 +7,13 @@ date: 2026-01-01
|
|||
domain: health
|
||||
secondary_domains: [ai-alignment]
|
||||
format: company-announcement
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -68,3 +72,15 @@ This creates a two-track clinical AI story: (1) Abridge/ambient scribes for docu
|
|||
PRIMARY CONNECTION: [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]]
|
||||
WHY ARCHIVED: Significant scale update — the existing claim understates 2026 metrics by an order of magnitude. Also: USMLE 100% creates the benchmark vs. outcomes tension in practice, not theory.
|
||||
EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim
|
||||
|
||||
|
||||
## Key Facts
|
||||
- OpenEvidence reached 8.5M+ clinical consultations/month in 2025
|
||||
- OpenEvidence reached 20M clinical consultations/month by January 2026
|
||||
- OpenEvidence achieved 1 million clinical consultations in one day on March 10, 2026
|
||||
- OpenEvidence Series D: $250M led by Thrive Capital and DST Global (January 2026)
|
||||
- OpenEvidence valuation: $6B → $12B in 3 months
|
||||
- OpenEvidence is the first AI to score 100% on the United States Medical Licensing Examination (USMLE) across all parts
|
||||
- 44% of physicians concerned about accuracy and risk of misinformation with clinical AI
|
||||
- 19% of physicians concerned about lack of physician oversight or explainability with clinical AI
|
||||
- OpenEvidence used across 10,000+ hospitals and medical centers nationwide
|
||||
|
|
|
|||
Loading…
Reference in a new issue